Clinical value of continuous administration of sorafenib in combination with modified transarterial chemoembolization in patients with unresectable hepatocellular carcinoma

被引：0
|
作者：
HUANG Yong-hui [1 ]
CHEN Wei [1 ]
LI Jia-ping [1 ]
CHEN Bin [1 ]
YANG Jian-yong [1 ]
机构：
[1] Department of Interventional Radiology,First Affiliated Hospital of Sun Yat-sen University
来源：
中华医学杂志（英文版） | 2013年 / 126卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R735.7 [肝肿瘤];
学科分类号：
100214 ;
摘要：
Hepatocellular carcinoma(HCC)is a major threat to human health in China with high morbidity and mortality.Surgical resection and liver transplantation are the most promising treatments for HCC.The majority of patients,however,are not eligible for surgery due to advanced tumor,multifocal disease or poor liver reserve.Recently,transarterial chemoembolization(TACE)improved survival compared with best supportive care in
引用
收藏
页码：385 / 386
相关论文
共 50 条
  • [1] Clinical value of continuous administration of sorafenib in combination with modified transarterial chemoembolization in patients with unresectable hepatocellular carcinoma
    Huang Yong-hui
    Chen Wei
    Li Jia-ping
    Chen Bin
    Yang Jian-yong
    CHINESE MEDICAL JOURNAL, 2013, 126 (02) : 385 - 386
  • [2] Continuous Administration of Sorafenib in Combination with Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma: Results of a Phase I Study
    Dufour, Jean-Francois
    Hoppe, Hanno
    Heim, Markus H.
    Helbling, Beat
    Maurhofer, Olivier
    Szucs-Farkas, Zsolt
    Kickuth, Ralph
    Borner, Markus
    Candinas, Daniel
    Saar, Bettina
    ONCOLOGIST, 2010, 15 (11): : 1198 - 1204
  • [3] Sorafenib plus transarterial chemoembolization for unresectable hepatocellular carcinoma
    Tsilimigras, Diamantis I.
    Pawlik, Timothy M.
    ANNALS OF TRANSLATIONAL MEDICINE, 2020, 8 (23)
  • [4] Safety of transarterial chemoembolization plus sorafenib combination treatment in unresectable hepatocellular carcinoma
    Sinakos, Emmanouil
    Dedes, Ioannis
    Papalavrentios, Lavrentis
    Drevelegas, Antonios
    Akriviadis, Evangelos
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2010, 45 (04) : 511 - 512
  • [5] Sorafenib in combination with transarterial chemoembolization and radiofrequency ablation in the treatment for unresectable hepatocellular carcinoma
    Yong Li
    You-Bing Zheng
    Wei Zhao
    Bing Liu
    Bao-Shan Hu
    Xu He
    Jian-Wen Huang
    Li-Gong Lu
    Medical Oncology, 2013, 30
  • [6] Sorafenib in combination with transarterial chemoembolization and radiofrequency ablation in the treatment for unresectable hepatocellular carcinoma
    Li, Yong
    Zheng, You-Bing
    Zhao, Wei
    Liu, Bing
    Hu, Bao-Shan
    He, Xu
    Huang, Jian-Wen
    Lu, Li-Gong
    MEDICAL ONCOLOGY, 2013, 30 (04)
  • [7] PHASE II STUDY OF THE CONCURRENT COMBINATION OF CONVENTIONAL TRANSARTERIAL CHEMOEMBOLIZATION AND SORAFENIB FOR PATIENTS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA
    Park, Joong-Won
    Kim, Hwi Young
    Ahn, Sang Bu
    Choi, Joon-Il
    Woo, Sang Myung
    Kim, Hyun-Beom
    KoH, Young Hwan
    Nam, Byung Ho
    HEPATOLOGY, 2011, 54 : 1443A - 1443A
  • [8] THE SAFETY AND EFFICACY OF SORAFENIB COMBINED WITH TRANSARTERIAL CHEMOEMBOLIZATION FOR PATIENTS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA
    Shao, W.
    Cong, N.
    Song, J.
    ANNALS OF ONCOLOGY, 2012, 23 : 161 - 161
  • [9] Lenvatinib in combination with transarterial chemoembolization vs. sorafenib in combination with transarterial chemoembolization for unresectable hepatocellular carcinoma: A network meta-analysis
    Li, Yong
    Liu, Xingyu
    Liu, Junning
    Yang, Linfeng
    Wei, Song
    Li, Jijiang
    Gan, Huixin
    Ma, Ting
    Yi, Pengsheng
    ONCOLOGY LETTERS, 2024, 28 (02)
  • [10] Sorafenib in Combination With Transarterial Chemoembolization for the Treatment of Hepatocellular Carcinoma
    Geschwind, Jean-Francois H.
    Chapiro, Julius
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2016, 14 (08) : 585 - 587
12345